en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
1/2007
vol. 45
 
Share:
Share:
more
 
 
abstract:

Original paper
Leflunomide in treatment of rheumatoid arthritis patients

Maria Rell-Bakalarska
,
Lidia Rutkowska-Sak
,
Małgorzata Kwiatkowska
,
Barbara Lisowska
,
Elżbieta Wojtecka-Łukasik
,
Sławomir Maśliński

Reumatologia 2007; 45, 1: 6–10
Online publish date: 2007/03/12
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The aim of this study was to investigate the effectiveness and safety of leflunomide in the treatment of rheumatoid arthritis (RA). Therapy with leflunomide was performed on 276 patients with active RA, defined by a disease activity score (DAS). All patients had previously been given conventional drug treatment without positive effects. The mean duration of leflunomide treatment was 16 months. Adverse events related to leflunomide therapy were evaluated. Before and after treatment, the serum activity of cartilage enzymes (NAH-ase and NTPPH-ase) was normal. The efficacy of leflunomide was shown in 70% of cases. This therapy proved ineffective in approximately 13% of patients. The results of this study demonstrated that leflunomide treatment had to be discontinued in 18% of patients because of adverse effects.
keywords:

rheumatoid arthritis, leflunomide, effectiveness and safety, cartilage enzymes







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.